Clinical Trial Update: Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure [Phase 1]

View source ↗

Summary

A Phase 1/2 trial of CTO in combination with Bevacizumab for recurrent malignant glioma after Bevacizumab failure has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CTO

Snippet

Sponsor: Annick Desjardins | Conditions: Malignant Glioma (WHO Grade III or IV) | Phase 1 | Status: TERMINATED